VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis
- 1 December 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 38 (12) , 1834-1845
Abstract
Patients with classical melorheostosis exhibit exuberant bone overgrowth in the appendicular skeleton, resulting in pain and deformity with no known treatment. Most patients have somatic, mosaic mutations in MAP2K1 (encoding the MEK1 protein) in osteoblasts and overlying skin. As with most rare bone diseases, lack of affected tissue has limited the opportunity to understand how the mutation results in excess bone formation. The aim of this study was to create a cellular model to study melorheostosis. We obtained patient skin cells bearing the MAP2K1 mutation (affected cells), and along with isogenic control normal fibroblasts reprogrammed them using the Sendai virus method into induced pluripotent stem cells (iPSCs). Pluripotency was validated by marker staining and embryoid body formation. iPSCs were then differentiated to mesenchymal stem cells (iMSCs) and validated by flow cytometry. We confirmed retention of the MAP2K1 mutation in iMSCs with polymerase chain reaction (PCR) and confirmed elevated MEK1 activity by immunofluorescence staining. Mutation-bearing iMSCs showed significantly elevated vascular endothelial growth factor (VEGF) secretion, proliferation and collagen I and IV secretion. iMSCs were then differentiated into osteoblasts, which showed increased mineralization at 21 days and increased VEGF secretion at 14 and 21 days of differentiation. Administration of VEGF to unaffected iMSCs during osteogenic differentiation was sufficient to increase mineralization. Blockade of VEGF by bevacizumab reduced mineralization in iMSC-derived affected osteoblasts and in affected primary patient-derived osteoblasts. These data indicate that patient-derived induced pluripotent stem cells recreate the elevated MEK1 activity, increased mineralization, and increased proliferation seen in melorheostosis patients. The increased bone formation is driven, in part, by abundant VEGF secretion. Modifying the activity of VEGF (a known stimulator of osteoblastogenesis) represents a promising treatment pathway to explore. iPSCs may have wide applications to other rare bone diseases. © 2023 American Society for Bone and Mineral Research (ASBMR).Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
This publication has 31 references indexed in Scilit:
- Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditionsNature Protocols, 2012
- The role of vascular endothelial growth factor in ossificationInternational Journal of Oral Science, 2012
- The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formationMolecular Biology of the Cell, 2011
- MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomasCell Cycle, 2009
- VEGF improves survival of mesenchymal stem cells in infarcted heartsBiochemical and Biophysical Research Communications, 2008
- Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung AdenocarcinomaCancer Research, 2008
- VEGF Improves, Whereas sFlt1 Inhibits, BMP2-Induced Bone Formation and Bone Healing Through Modulation of AngiogenesisJournal of Bone and Mineral Research, 2005
- Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cellsJournal of Cellular Physiology, 2005
- Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrixMicroscopy Research and Technique, 2002
- Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnoverProceedings of the National Academy of Sciences, 2002